Enanta Pharmaceuticals (ENTA) Other Non-Current Assets (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Other Non-Current Assets of $144000.0 for Q1 2026, up 46.94% year-on-year from $98000.0 in Q1 2025, and up 54.84% on a QoQ basis from $93000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Other Non-Current Assets data on file, last reported at $144000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 46.94% year-over-year to $144000.0; the trailing twelve-month figure through Mar 2026 stood at $144000.0 (up 46.94% YoY), and the FY2025 full-year result was $92000.0, down 97.26% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $144000.0, up from $93000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $4.0 million in Q2 2022 and bottomed at $92000.0 in Q3 2025.
- The 5-year median for Other Non-Current Assets is $830000.0 (2023), against an average of $1.9 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets soared 4213.04%; it then plunged 97.26% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $4.0 million in 2022, then plunged by 80.72% to $765000.0 in 2023, then soared by 339.22% to $3.4 million in 2024, then tumbled by 97.23% to $93000.0 in 2025, then jumped by 54.84% to $144000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $144000.0 (Q1 2026), $93000.0 (Q4 2025), and $92000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 144,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 144,000.00 |
| Dec 31, 2025 | 93,000.00 |
| Sep 30, 2025 | 92,000.00 |
| Jun 30, 2025 | 3.36 Mn |
| Mar 31, 2025 | 98,000.00 |
| Dec 31, 2024 | 3.36 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Jun 30, 2024 | 105,000.00 |
| Mar 31, 2024 | 187,000.00 |
| Dec 31, 2023 | 765,000.00 |
| Sep 30, 2023 | 3.97 Mn |
| Jun 30, 2023 | 830,000.00 |
| Mar 31, 2023 | 3.97 Mn |
| Dec 31, 2022 | 3.97 Mn |
| Sep 30, 2022 | 3.97 Mn |
| Jun 30, 2022 | 3.97 Mn |
| Mar 31, 2022 | 608,000.00 |
| Dec 31, 2021 | 92,000.00 |
| Sep 30, 2021 | 608,000.00 |
| Jun 30, 2021 | 92,000.00 |
| Mar 31, 2021 | 608,000.00 |
| Dec 31, 2020 | 92,000.00 |
| Sep 30, 2020 | 608,000.00 |
| Jun 30, 2020 | 92,000.00 |
| Mar 31, 2020 | 92,000.00 |
| Dec 31, 2019 | 608,000.00 |
| Sep 30, 2019 | 92,000.00 |
| Jun 30, 2019 | 608,000.00 |
| Mar 31, 2019 | 608,000.00 |
| Dec 31, 2018 | 608,000.00 |
| Sep 30, 2018 | 608,000.00 |
| Jun 30, 2018 | 608,000.00 |
| Mar 31, 2018 | 608,000.00 |
| Dec 31, 2017 | 608,000.00 |
| Sep 30, 2017 | 608,000.00 |
| Jun 30, 2017 | 608,000.00 |
| Mar 31, 2017 | 608,000.00 |
| Dec 31, 2016 | 608,000.00 |
| Sep 30, 2016 | 608,000.00 |
| Jun 30, 2016 | 608,000.00 |
| Mar 31, 2016 | 608,000.00 |
| Dec 31, 2015 | 608,000.00 |
| Sep 30, 2015 | 608,000.00 |
| Jun 30, 2015 | 608,000.00 |
| Mar 31, 2015 | 608,000.00 |
| Dec 31, 2014 | 436,000.00 |
| Sep 30, 2014 | 436,000.00 |
| Jun 30, 2014 | 436,000.00 |
| Mar 31, 2014 | 436,000.00 |
| Dec 31, 2013 | 436,000.00 |
| Sep 30, 2013 | 436,000.00 |
| Jun 30, 2013 | 436,000.00 |
| Mar 31, 2013 | 436,000.00 |
| Sep 30, 2012 | 436,000.00 |